Associated Papers
Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.
Charoenngam N et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2025
Early-Onset Sarcoma With Germline MAX Variant: Expanding the Spectrum in Hereditary Pheochromocytoma and Paraganglioma.
Eren A et al.
Jcem Case Reports, 2025
Unlocking the Genetic Secrets of Acromegaly: Exploring the Role of Genetics in a Rare Disorder.
Balinisteanu I et al.
Current Issues in Molecular Biology, 2024
Updates on the genetics of multiple endocrine neoplasia.
Sahakian N et al.
Annales D'endocrinologie, 2024
Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B et al.
Frontiers in Endocrinology, 2024
Primary Hyperparathyroidism in a Patient With Bilateral Pheochromocytoma and a Mutation in the Tumor Suppressor MAX.
Charoenngam N et al.
Jcem Case Reports, 2023
Bilateral Pheochromocytoma with Germline MAX Variant without Family History.
Hata S et al.
Clinics and Practice, 2022
35645312 (PubMed )
Supplement: clinpract-12-00035-s001.zip › clinpract-1702561-supplementary.pdf
Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?
Seabrook AJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2021
Familial Acromegaly and Bilateral Asynchronous Pheochromocytomas in a Female Patient With a MAX Mutation: A Case Report.
Mamedova E et al.
Frontiers in Endocrinology, 2021
Select a paper to view details